Last reviewed · How we verify
KETAMINE, MIDAZOLAM
KETAMINE, MIDAZOLAM is a Dissociative anesthetic and benzodiazepine combination Small molecule drug developed by Soroka University Medical Center. It is currently FDA-approved for Procedural sedation and analgesia, Emergency department sedation, Rapid sequence intubation.
Ketamine and midazolam together provide dissociative anesthesia and sedation by blocking NMDA receptors and enhancing GABAergic inhibition, respectively.
Ketamine and midazolam are used in medical settings for various purposes, including sedation and anesthesia, as seen in studies for conditions such as non-small cell lung cancer and laceration repair. Both ketamine and midazolam act as positive allosteric modulators of the GABA-A receptor, an anion channel, which is a mechanism of action shared by midazolam.
At a glance
| Generic name | KETAMINE, MIDAZOLAM |
|---|---|
| Sponsor | Soroka University Medical Center |
| Drug class | Dissociative anesthetic and benzodiazepine combination |
| Target | NMDA receptor (ketamine); GABA-A receptor (midazolam) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Sedation |
| Phase | FDA-approved |
Mechanism of action
Ketamine is a non-competitive NMDA receptor antagonist that produces dissociative anesthesia and analgesia, while midazolam is a benzodiazepine that potentiates GABA-A receptor signaling to enhance sedation and anxiolysis. This combination is used clinically to achieve rapid sedation with analgesia while maintaining airway reflexes and spontaneous respiration.
Approved indications
- Procedural sedation and analgesia
- Emergency department sedation
- Rapid sequence intubation
Common side effects
- Dissociation/emergence reactions
- Respiratory depression
- Hypotension
- Tachycardia
- Increased salivation
- Nausea/vomiting
Key clinical trials
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- Ketamine for Multiple Sclerosis Fatigue (PHASE2)
- The Impact of a Shared Decision-Making Intervention on Intraoperative Patient Experience During Elective Cesarean Delivery Under Spinal Anesthesia (NA)
- A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (PHASE3)
- Ketamine, SGB and Combination Treatment for TBI (PHASE2)
- Prospective IR-led Sedation Feasibility (PHASE1, PHASE2)
- Ketamine for Treatment-Resistant Bipolar Disorder (PHASE2)
- Comparative Assessment of Oral Premedication Regimens in Pediatric Ambulatory Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KETAMINE, MIDAZOLAM CI brief — competitive landscape report
- KETAMINE, MIDAZOLAM updates RSS · CI watch RSS
- Soroka University Medical Center portfolio CI
Frequently asked questions about KETAMINE, MIDAZOLAM
What is KETAMINE, MIDAZOLAM?
How does KETAMINE, MIDAZOLAM work?
What is KETAMINE, MIDAZOLAM used for?
Who makes KETAMINE, MIDAZOLAM?
What drug class is KETAMINE, MIDAZOLAM in?
What development phase is KETAMINE, MIDAZOLAM in?
What are the side effects of KETAMINE, MIDAZOLAM?
What does KETAMINE, MIDAZOLAM target?
Related
- Drug class: All Dissociative anesthetic and benzodiazepine combination drugs
- Target: All drugs targeting NMDA receptor (ketamine); GABA-A receptor (midazolam)
- Manufacturer: Soroka University Medical Center — full pipeline
- Therapeutic area: All drugs in Anesthesia and Sedation
- Indication: Drugs for Procedural sedation and analgesia
- Indication: Drugs for Emergency department sedation
- Indication: Drugs for Rapid sequence intubation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing